Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
GLOASIS trial (glofitamab): what clinicians have said so far
Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma
- NCT06558604 ↗
- Recruiting
- The Lymphoma Academic Research Organisation
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on GLOASIS (glofitamab plus venetoclax plus obinutuzumab; glofitamab plus venetoclax plus zanubrutinib plus obinutuzumab in high-risk mantle-cell lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on GLOASIS so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 YouTube videos | |
| 1 post on X |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Multicenter, Open-label Study Evaluating Glofitamab in Combination With Venetoclax Plus Zanubrutinib or Venetoclax Alone in Subjects With Untreated or Relapsed/Refractory High-risk Mantle-cell Lymphoma
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Lymphoma, Mantle-Cell
- Interventions
- Obinutuzumab; Glofitamab; Venetoclax Oral Product; Zanubrutinib Oral Capsule
- Arms
- Cohort A - POD24 · Experimental
- Cohort B - BTKI failure · Experimental
- Cohort C - first Line · Experimental
- Enrollment
- 100 (estimated)
- Primary outcomes
- PFS at the end of C17 (each cycle is 21 days)
- Sponsor
- The Lymphoma Academic Research Organisation with BeiGene, Hoffmann-La Roche
- Start
- Feb 21, 2025
- Primary completion
- May 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06558604 · updated Jul 10, 2026